AU2019385818B2 - Methods for determining disease risk combining downsampling of class-imbalanced sets with survival analysis - Google Patents

Methods for determining disease risk combining downsampling of class-imbalanced sets with survival analysis Download PDF

Info

Publication number
AU2019385818B2
AU2019385818B2 AU2019385818A AU2019385818A AU2019385818B2 AU 2019385818 B2 AU2019385818 B2 AU 2019385818B2 AU 2019385818 A AU2019385818 A AU 2019385818A AU 2019385818 A AU2019385818 A AU 2019385818A AU 2019385818 B2 AU2019385818 B2 AU 2019385818B2
Authority
AU
Australia
Prior art keywords
class
data
data set
imbalanced
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019385818A
Other languages
English (en)
Other versions
AU2019385818A1 (en
Inventor
Leigh Alexander
Gargi DATTA
Yolanda HAGAR
Michael HINTERBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Operating Co Inc
Original Assignee
Somalogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Operating Co Inc filed Critical Somalogic Operating Co Inc
Publication of AU2019385818A1 publication Critical patent/AU2019385818A1/en
Assigned to SOMALOGIC OPERATING CO., INC. reassignment SOMALOGIC OPERATING CO., INC. Request for Assignment Assignors: SOMALOGIC, INC.
Application granted granted Critical
Publication of AU2019385818B2 publication Critical patent/AU2019385818B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/117—Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4866—Evaluating metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4869—Determining body composition
    • A61B5/4872—Body fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7221—Determining signal validity, reliability or quality
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235—Details of waveform analysis
    • A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Signal Processing (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dentistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cardiology (AREA)
  • Mathematical Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Evolutionary Computation (AREA)
  • Fuzzy Systems (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Mathematical Analysis (AREA)
  • Computational Mathematics (AREA)
  • Algebra (AREA)
  • Mathematical Optimization (AREA)
AU2019385818A 2018-11-29 2019-11-21 Methods for determining disease risk combining downsampling of class-imbalanced sets with survival analysis Active AU2019385818B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862773028P 2018-11-29 2018-11-29
US62/773,028 2018-11-29
US201862783733P 2018-12-21 2018-12-21
US62/783,733 2018-12-21
PCT/US2019/062561 WO2020112478A1 (en) 2018-11-29 2019-11-21 Methods for determining disease risk combining downsampling of class-imbalanced sets with survival analysis

Publications (2)

Publication Number Publication Date
AU2019385818A1 AU2019385818A1 (en) 2021-07-08
AU2019385818B2 true AU2019385818B2 (en) 2025-04-24

Family

ID=70852605

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019385818A Active AU2019385818B2 (en) 2018-11-29 2019-11-21 Methods for determining disease risk combining downsampling of class-imbalanced sets with survival analysis

Country Status (10)

Country Link
US (1) US20220015714A1 (cg-RX-API-DMAC7.html)
EP (1) EP3886696A4 (cg-RX-API-DMAC7.html)
JP (2) JP7680950B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210099605A (cg-RX-API-DMAC7.html)
CN (1) CN113271849B (cg-RX-API-DMAC7.html)
AU (1) AU2019385818B2 (cg-RX-API-DMAC7.html)
CA (1) CA3120716A1 (cg-RX-API-DMAC7.html)
IL (1) IL283467A (cg-RX-API-DMAC7.html)
SG (1) SG11202105063QA (cg-RX-API-DMAC7.html)
WO (1) WO2020112478A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11996201B2 (en) * 2021-03-04 2024-05-28 Abbott Laboratories Technology to automatically identify the most relevant health failure risk factors
JP7322918B2 (ja) * 2021-03-29 2023-08-08 横河電機株式会社 プログラム、情報処理装置、及び学習モデルの生成方法
KR102393367B1 (ko) 2021-11-15 2022-05-03 오브젠 주식회사 생존 분석 시스템 및 그 제어방법
KR102424884B1 (ko) 2021-11-18 2022-07-27 오브젠 주식회사 생존 데이터 정제 서버와 생존 데이터 분석 서버를 포함하는 시스템 및 그 제어방법
CN114548327A (zh) * 2022-04-27 2022-05-27 湖南工商大学 基于平衡子集的软件缺陷预测方法、系统、设备及介质
CN115114270B (zh) * 2022-06-14 2024-08-02 马上消费金融股份有限公司 数据降采样方法及装置、电子设备、计算机可读存储介质
KR102688743B1 (ko) * 2023-08-16 2024-07-26 렉스이노베이션 주식회사 분산 배터리의 soh에 기초하여 이상을 탐지하는 방법
US20250069754A1 (en) * 2023-08-22 2025-02-27 Elythea, Inc. Predicting risk of pregnancy-related complications using machine learning
CN121015165A (zh) * 2025-06-30 2025-11-28 延边大学 基于多模态特征融合的睡眠呼吸暂停识别方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180226153A1 (en) * 2015-09-30 2018-08-09 Inform Genomics, Inc. Systems and Methods for Predicting Treatment-Regimen-Related Outcomes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7982066B2 (en) * 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
AU2010328019A1 (en) * 2009-12-09 2012-06-28 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
US20120271553A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with clusters
WO2018048960A1 (en) 2016-09-07 2018-03-15 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN104573708A (zh) * 2014-12-19 2015-04-29 天津大学 组合降采样极限学习机
WO2017214397A1 (en) 2016-06-08 2017-12-14 University Of Iowa Research Foundation Compositions and methods for detecting predisposition to cardiovascular disease
GB201614394D0 (en) * 2016-08-23 2016-10-05 Imp Innovations Ltd Method
CA3052349C (en) 2017-02-02 2024-06-04 B.R.A.H.M.S Gmbh Proadm as marker indicating an adverse event
AU2018100796A4 (en) * 2018-06-14 2018-07-19 Macau University Of Science And Technology A genetic feature identifying system and a search method for identifying features of genetic information

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180226153A1 (en) * 2015-09-30 2018-08-09 Inform Genomics, Inc. Systems and Methods for Predicting Treatment-Regimen-Related Outcomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUAN HAO ET AL: "Classifying MCI Subtypes in Community-Dwelling Elderly Using Cross-Sectional and Longitudinal MRI-Based Biomarkers", FRONTIERS IN AGING NEUROSCIENCE, vol. 9, no. 9, 26 September 2017 (2017-09-26), pages 1 - 13, XP055942783 *

Also Published As

Publication number Publication date
WO2020112478A1 (en) 2020-06-04
EP3886696A4 (en) 2022-08-24
KR20210099605A (ko) 2021-08-12
JP2022509835A (ja) 2022-01-24
US20220015714A1 (en) 2022-01-20
IL283467A (en) 2021-07-29
JP7680950B2 (ja) 2025-05-21
EP3886696A1 (en) 2021-10-06
CN113271849B (zh) 2024-08-30
AU2019385818A1 (en) 2021-07-08
CA3120716A1 (en) 2020-06-04
SG11202105063QA (en) 2021-06-29
JP2025061136A (ja) 2025-04-10
CN113271849A (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
US20220015714A1 (en) Methods For Determining Disease Risk Combining Downsampling of Class-Imbalanced Sets With Survival Analysis
Kukar et al. COVID-19 diagnosis by routine blood tests using machine learning
Amezquita et al. Orchestrating single-cell analysis with Bioconductor
Sweeney et al. A community approach to mortality prediction in sepsis via gene expression analysis
Aktar et al. Machine learning approach to predicting COVID-19 disease severity based on clinical blood test data: statistical analysis and model development
Schupp et al. Diagnostic and prognostic role of platelets in patients with sepsis and septic shock
Gultepe et al. From vital signs to clinical outcomes for patients with sepsis: a machine learning basis for a clinical decision support system
Zheng et al. Prospective accuracy for longitudinal markers
Günther et al. A computational pipeline for the development of multi-marker bio-signature panels and ensemble classifiers
Shi et al. Machine learning-based in-hospital mortality prediction of HIV/AIDS patients with Talaromyces marneffei infection in Guangxi, China
Melo et al. A machine learning application based in random forest for integrating mass spectrometry-based metabolomic data: a simple screening method for patients with Zika virus
Shen et al. Interpretable machine learning-based prediction of 28-day mortality in ICU patients with sepsis: a multicenter retrospective study
US20220084639A1 (en) Electronic Phenotyping Technique for Diagnosing Chronic Kidney Disease
Aguirre et al. Diagnostic performance of machine learning models using cell population data for the detection of sepsis: a comparative study
Gao et al. Enhancing fever of unknown origin diagnosis: machine learning approaches to predict metagenomic next-generation sequencing positivity
Esteban et al. Combination of exhaled volatile organic compounds with serum biomarkers predicts respiratory infection severity
Pecanha-Pietrobom et al. The clinical course of hospitalized moderately ill COVID-19 patients is mirrored by routine hematologic tests and influenced by renal transplantation
Mustafa A. Mohammad et al. Classifying the mortality of people with underlying health conditions affected by COVID‐19 using machine learning techniques
Selman et al. Artificial intelligence in idiopathic pulmonary fibrosis: advances, challenges and future directions
Matejin et al. Risk stratification and prediction of severity of COVID-19 infection in patients with preexisting cardiovascular disease
JP2019532410A (ja) 個人の生物学的ステータスを予測するためのシステム、方法および遺伝子シグネチャ
Sirbu et al. Early outcome detection for COVID-19 patients
Lai et al. A mixture model approach to the tests of concordance and discordance between two large-scale experiments with two-sample groups
Sritharan et al. Machine learning-based risk prediction of outcomes in patients hospitalized with COVID-19 in Australia: the AUS-COVID Score
Sweeney et al. Mortality prediction in sepsis via gene expression analysis: a community approach

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SOMALOGIC OPERATING CO., INC.

Free format text: FORMER APPLICANT(S): SOMALOGIC, INC.

FGA Letters patent sealed or granted (standard patent)